Klin Onkol. 2021 Summer;34(4):283-290. doi: 10.48095/ccko2021283.
Venous thromboembolism (VTE) is a frequent cause of morbidity and mortality in patients with cancer. Moreover, management of VTE is frequently connected with complications, namely risk of recurrent VTE and bleeding. Low molecular weight heparins (LMWH) therapy administrated for 3-6 months is currently considered a standard for the treatment of cancer-associated VTE (CA-VTE). Direct oral factor Xa inhibitors (FXaI) apixaban, edoxaban and rivaroxaban have emerged as a new possibility for long-term antithrombotic therapy for VTE. These agents expose several advantages in individuals with cancer, and might overcome several disadvantages connected with LMWH therapy.
First clinical studies with oral FXaI for the treatment of CA-VTE with very promising results were recently published. The article summarizes current data regarding the use of oral FXaI in the treatment of CA-VTE.
静脉血栓栓塞症（VTE）是癌症患者发病率和死亡率的一个常见原因。此外，VTE 的治疗常常与并发症有关，即复发性 VTE 和出血的风险。目前，低分子肝素（LMWH）治疗 3-6 个月被认为是癌症相关 VTE（CA-VTE）治疗的标准。直接口服因子 Xa 抑制剂（FXaI）阿哌沙班、依度沙班和利伐沙班已成为 VTE 长期抗血栓治疗的一种新选择。这些药物在癌症患者中具有多种优势，可能克服与 LMWH 治疗相关的一些缺点。
最近发表了一些关于口服 FXaI 治疗 CA-VTE 的非常有前景的初步临床研究。本文总结了目前关于口服 FXaI 在 CA-VTE 治疗中的应用的数据。
